In a phase 3 clinical trial, once-daily orforglipron outperformed semaglutide tablets, the best-known oral version of the GLP ...

Orforglipron, a novel oral nonpeptide GLP-1 receptor agonist (RA), led to a greater reduction in A1c and more significant weight loss compared to oral semaglutide in patients with type 2 diabetes (T2D ...

A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...

A NOVEL non-peptide glucagon-like peptide-1 receptor agonist pill is more effective for weight loss than oral semaglutide in patients with Type 2 diabetes, a 2026 Phase III trial ...

An investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, orforglipron (Eli Lilly), demonstrated superior ...

USA: Oral semaglutide may lower the risk of heart failure-related events in people with type 2 diabetes who already have heart failure, without increasing serious adverse events, a secondary analysis ...

The study suggests that the novel compound may offer superior glycaemic control and weight reduction compared with current ...

PHOENIX, AZ - February 27, 2026 - PRESSADVANTAGE - Phoenix NP, a women-focused telehealth medical practice based in ...

Once-daily orforglipron induced greater reductions in HbA1c and body weight than once-daily oral semaglutide for adults with type 2 diabetes, according to data from the ACHIEVE-3 trial published in ...

A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year ...

Ozempic (R) was approved by Health Canada in 2018. Ozempic (R) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control.